Hyperhomocystinemia and the prevalence of symptomatic atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: A retrospective study

Renal Failure

Volumn 25, Issue 5, 2003, Pages 765-774

  Chuang, Feng Rong ^a   Fang, Ji Tseng ^a   Chen, Jin Bor ^a   Lin, Chun Liang ^a   Chen, Hue Yong ^a   Lee, Ching Nun ^b   Wang, Pao Hui ^b   Lee, Chil Hsiung ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Atherosclerotic vascular disease; Hemodialysis; Hyperhomocystinemia

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TAIWAN;

AGED; ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 0141730374     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120024292     Document Type: Article

References (22)

1. Chauveau, P.; Chadefaux, B.; Coude, M.; Aupettt, J.; Hannedouche, T.; Kamoun, P.; Jungers, P. Hyperhomocystinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993, 41 (suppl), S72-S77.
2. Arnadottir, M.; Brattstrom, L.; Simonsen, O.; Thysell, H.; Hultbero, B.; Andersson, A.; Nilsson-Ehle, P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin. Nephrol. 1993, 40, 236-240.
3. Bachmann, J.; Tepel, M.; Raidt, H.; Riezler, R.; Graefe, U.; Langer, K.; Zidek, W. Hyperhomocystinemia and the risk for vascular disease in hemodialysis patients. J. Am. Soc. Nephrol. 1995, 6, 121-125.
4. Bostom, A.G.; Shemin, D.; Lapane, K.L.; Miller, J.W.; Sutherland, P.; Nadeau, M.; Seyoum, E.; Hartman, W.; Prior, R.; Wilson, P.W.F.; Selhub, J. Hyperhomocystinemia and traditional cardiovascular disease risk factors in endstage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114, 93-103.
5. Robinson, K.; Gupta, A.; Dennis, V.W.; Arheart, K.; Chaudhary, D.; Green, R.; Vigo, P.; Mayer, E.L.; Selhub, J.; Kutner, M.; Jacobsen, D.W. Hyperhomocystinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996, 94, 2743-2748.
6. Bostom, A.G.; Lathrop, L. Hyperhomocystinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997, 52, 10-20.
7. Moustapha, A.; Naso, A.; Nahlawi, M.; Gupta, A.; Arheart, K.L.; Jacobsen, D.W.; Robinson, K.; Dennis, V.W. Prospective study of hyperhomocystinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97, 138-141.
8. Manns, B.J.; Burgess, E.D.; BSc-Hyndman, M.E.; Parsons, H.G.; Schaefer, J.P.; Scott-Douglas, N.W. Hyperhomocystinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kid. Dis. 1999, 34, 669-677.
9. Manns, B.J.; Burgress, E.D.; Parsons, H.G.; Schaefer, J.P.; Hyndman, M.E.; Scott-Douglas, N.W. Hyperhomocystinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney. Int. 1999, 55, 315-320.
10. Moustapha, A.; Gupta, A.; Robinson, K.; Arheart, K.; Jacobsen, D.W.; Schreiber, M.J.; Dennis, V.W. Prevalence and determinants of hyperhomocystinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999, 55, 1470-1475.
11. Bostom, A.G.; Shemin, D.; Verhoef, P.; Nadeau, M.R.; Jacques, P.F.; Selhub, J.; Dworkin, L.; Rosenberg, I.H. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. American Heart Association, Inc. 1997, 69, 2554-2558.
12. Bostom, A.; Brosnan, J.T.; Hall, B.; Nadeau, M.R.; Selhub, J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995, 116, 59-62.
13. Jacob, R.A.; Wu, M.M.; Henning, S.M.; Swendseid, M.E. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J. Nutr. 1994, 124, 1072-1080.
14. 6, and folate nutritional status in men with hyperhomocystinemia. Am. J. Clin. Nutr. 1993, 57, 47-53.
15. Tremblay, R.; Bonnardeaux, A.; Gradah, D.; Busque, L.; Lebrun, M.; Ouimet, D.; Leblanc, M. Hyperhomocystinemia in hemodialysis patients: effect of 12-month supplementation with hydrosoluble vitamins. Kidney Int. 2000, 58, 851-858.
16. Hultberg, B.; Andersson, A.; Sterner, G. Plasma homocysteine in renal failure. Clin. Nephrol. 1993, 41, 230-234.
17. Bostom, A.; Lathrop, L. Hyperhomocystinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997, 52, 10-20.
18. Green, D.; Stone, N.J.; Krumlovsky, F.A. Putative atherogenic factors in patients with chronic renal failure. Prog. Cardiovasc. Dis. 1983, 26, 133-140.
19. Tamura, T.; Bergman, S.M.; Morgan, S.L. Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis. Am. J. Kid. Dis. 1998, 32, 475-481.
20. 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst (e) inemia. Kidney Int. 2001, 59, 1103-1109.
21. Lasseur, C.; Parrot, F.; Delmas, Y.; Level, C.; Ged, C.; Redonnet-Vernhet, I.; Montaudon, D.; Combe, C.; Chauveau, P. Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism. Journal of Nephrology 2001, 14, 32-35.
22. 12 levels in chronic high-flux hemodialysis patients. Nephron 1997, 75, 259-263.